Skip to main content
Premium Trial:

Request an Annual Quote

UPDATE: Lion Licenses SRS Platform to Affymetrix

This story has been updated from a previous version.

NEW YORK, May 17 - Lion Bioscience has licensed its SRS platform to Affymetrix for use in internal R&D as well as for a customer portal, Lion said Thursday.

The licensing deal will be for three years, Jan Mous, chief scientific officer of Lion, told GenomeWeb. No other terms of the agreement were disclosed, though Mous did call the size of the deal  "larger than usual" for Lion.

Affymetrix has previously said it planned to build a web portal that would connect information generated by its chips to the genome and vice versa.   

"Affymetrix's new web portal will offer our customers added value and enable them to more rapidly understand biological functions of genes analyzed using our expression arrays, and thus resulting in the acceleration of new discoveries," David Craford, Affymetrix vice president of marketing, instrumentation and informatics, said in a statement.

The portal will be offered online free as a resource for systems annotation in a "phase one" rollout to customers this summer, Craford told GenomeWeb. How Affymetrix uses the portal in "phase two" of its development "will be based on customer feedback," said Craford.

Affymetrix plans to use the SRS platform in its R&D efforts to build and maintain databases used to design and produce its GeneChip arrays, said Craford.

Lion's SRS system integrates more than 400 diverse databases, according to the company. The company's customers include Celera, where it is used as a web portal for its Discovery System.

The current deal with Affymetrix is "in line with our strategy that leaders in the field use the same technology," said Mous.

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.